Skip to content

Innovative drug delivery platform for the benefit of patients and pharma industry

Interim Report Q1 2022

LIDDS published its interim report for January-March 2022 on May 24, 2022.

The share

Loading...

"Lately, we have been making great progress in our projects."

– Nina Herne, CEO
February 23, 2022

lidds-nanosolid-homepage-module

LIDDS' optimal drug delivery for patients and partners

LIDDS is based on the proprietary drug delivery technology NanoZolid, a versatile technology that can be used to formulate most drugs and solve problems within many indication areas, offering good growth opportunities. The IP position is strong, providing coverage for both the technology and products based on the technology until at least 2037. LIDDS has developed its own pipeline within the large and growing oncology area where unique solutions can be provided. The ability to reformulate and improve existing drugs means lower development costs and higher chance to market. The technology is validated both through established partnerships and clinical trials.

LIDDS board and management has a strong track record of building and operating pharmaceutical and life-science businesses.

lidds-module-1

NanoZolid® – more precise drug treatment with higher local effect and reduced systemic side effects

NanoZolid is a technology for local, controlled, and sustained release of drugs over time. The purpose is primarily to make drug treatments more precise, to induce a higher local effect and to reduce systemic side effects.

NanoZolid-formulated drugs are injected as a suspension directly into or near the tumor. The suspension solidifies and forms a local solid drug depot which releases the drug in a controlled manner over a longer and defined period. As the depot breaks down, it is completely absorbed into the body without leaving any residual products.

Pipeline

lidds-pipeline-module-image-d

Liproca Depot

Liproca Depot is being developed for prostate cancer. Liproca Depot is NanoZolid-formulated 2- hydroxyflutamide (2-HOF) which is an anti-androgen drug. 2-HOF is normally being used systemically for treating prostate cancer patients before radical treatments, but often with severe side-effects. These can be avoided with local administration of Liproca Depot in the tumor.

lidds-nanodotax-module

Nanodotax

Nanodotax is NanoZolid-formulated docetaxel which is a commonly used chemotherapeutic drug that has been approved for several oncological conditions. Nanodotax has shown to be safe and well tolerated in a phase I study. In addition there was an observed effect on systemic and local immunological biomarkers indicating that the immune system was responding positively and specifically to the treatment.

Nanoimod and nanoxan

Nanoimod and nanoxan is a NanoZolid formulated combination therapy consisting of a TLR9 agonist and a non-disclosed substance. The combination has shown signs of immunoactivity in untreated tumors (abscopal effect) in preclinical studies.

lidds-module-rnd-2

Partnerships

LIDDS has entered into a research and development agreement with Johnson & Johnson Enterprise Innovation Incorporated and a license agreement for China with Puheng Pharma for Liproca Depot.

Member of